Digest Network Come funziona
Network
/
Società
No
Non verificato

Novartis Pharma AG

Di cosa scriviamo

Annunci EconomiciFarmaceuticaManagement/Organizzazione AziendaleMedicina Salute BenesserePubblicità/Marketing/Media/Comunicazione

73 comunicati stampa

Guarda tutti i comunicati
16/01/2026
Farmaceutica
Annunci Economici
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
09/01/2026
Farmaceutica
Annunci Economici
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
19/12/2025
Farmaceutica
Annunci Economici
Novartis and US government reach agreement on lowering drug prices in the US
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
09/12/2025
Farmaceutica
Annunci Economici
Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
09/12/2025
Farmaceutica
Annunci Economici
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
24/11/2025
Farmaceutica
Annunci Economici
Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
24/11/2025
Farmaceutica
Medicina Salute Benessere
Annunci Economici
Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
19/11/2025
Farmaceutica
Annunci Economici
Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
19/11/2025
Farmaceutica
Annunci Economici
Novartis announces plans to build flagship manufacturing hub in North Carolina
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0
12/11/2025
Farmaceutica
Annunci Economici
Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance
Fonte
Novartis Pharma AG
Emittente
GLOBENEWSWIRE
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0